Association of baseline characteristics and early vision response with 2-year vision outcomes in the comparison of AMD Treatments Trials (CATT)

Ophthalmology

Volumn 122, Issue 12, 2015, Pages 2523-2531.e1

  Ying, Gui Shuang ^a   Maguire, Maureen G ^a   Daniel, Ebenezer ^a   Ferris, Frederick L ^b   Jaffe, Glenn J ^c   Grunwald, Juan E ^a   Toth, Cynthia A ^c   Huang, Jiayan ^a   Martin, Daniel F ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL EYE INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE MOVEMENT; FEMALE; GEOGRAPHIC ATROPHY; HUMAN; LACRIMAL FLUID; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINAL THICKNESS; STEREOSCOPIC VISION; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANIBIZUMAB; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84948074611     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.08.015     Document Type: Article

References (25)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier, et al. for the MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
2. D.M. Brown, P.K. Kaiser, M. Michels, et al. for the ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
3. P.J. Rosenfeld, A.A. Moshfeghi, and C.A. Puliafito Optical coherence tomography after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 2005 331 335
4. R.L. Avery, D.J. Pieramici, M.D. Rabena, and et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 2006 363 372
5. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
6. The CATT Research Group Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results Ophthalmology 119 2012 1388 1398
7. J.S. Heir, D.M. Brown, V. Chong, et al. for the VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
8. G.S. Ying, J. Huang, M.G. Maguire, et al. for the CATT Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
9. G.S. Ying, B.J. Kim, M.G. Maguire, et al. for the CATT Research Group Sustained visual acuity loss in the in the Comparison of AMD Treatments Trials (CATT) JAMA Ophthalmol 132 2014 915 921
10. B.J. Kim, G.S. Ying, J. Huang, et al. for the CATT Research Group Sporadic visual acuity loss in the comparison of age-related macular degeneration treatments trials (CATT) Am J Ophthalmol 158 2014 128 135
11. S. Hagstrom, G.S. Ying, G.J. Pauer, et al. for the CATT Research Group Pharmacogenetics of anti-VEGF therapy in the Comparison of AMD Treatments Trials (CATT) Ophthalmology 120 2013 593 599
12. S. Hagstrom, G.S. Ying, G.J. Pauer, et al. for the CATT Research Group VEGF-A and VEGFR-2 gene polymorphisms and response to anti-VEGF therapy in the Comparison of AMD Treatments Trials (CATT) JAMA Ophthalmol 132 2014 521 527
13. J.E. Grunwald, E. Daniel, G.S. Ying, et al. for the CATT Research Group Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 1634 1641
14. F.C. DeCroos, C.A. Toth, S.S. Stinnett, et al. for the CATT Research Group Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 2549 2557
15. R.W. Beck, P.S. Moke, A.H. Turpin, and et al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol Am J Ophthalmol 135 2003 194 205
16. X.L. Meng, R. Rosenthal, and D.B. Rubin Comparing correlated correlation coefficients Psychol Bull 111 1992 172 175
17. Y. Yonekawa, C. Andreoli, J.A. Miller, and et al. Conversion to Aflibercept for chronic refractory or recurrent neovascular Age-related Macular Degeneration Am J Ophthalmol 156 2013 29 35
18. J.A. Eadie, J.L. Gottlieb, M.S. Ip, and et al. Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration Ophthalmic Surg Lasers Imaging Retina 9 2014 1 4
19. C. Ehlken, S. Jungmann, D. Bohringer, and et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD Eye 28 2014 538 545
20. M. Aslankurt, L. Aslan, A. Aksoy, and et al. The results of switching between 2 anti-VEGF drugs bevacizumab and ranibizumab in the treatment of neovascular age-related macular degeneration Eur J Ophthalmol 23 2013 553 557
21. H. Cho, C.P. Shah, M. Weber, and J.S. Heier Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab Br J Ophthalmol 97 2013 1032 1035
22. B. Bakall, J.C. Folk, H.C. Boldt, and et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab Am J Ophthalmol 156 2013 15 22.e1
23. R.P. Finger, S.S. Wickremasinghe, P.N. Baird, and R.H. Guymer Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration Surv Ophthalmol 59 2014 1 18
24. I.V.A.N. The Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
25. B.G. Busbee, A.C. Ho, D.M. Brown, et al. for the HARBOR Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056